News From Sentrimed
Sentrimed is a clinical-stage biopharmaceutical company creating safer, oral oncology therapies that target podoplanin (PDPN), a prognostic cancer biomarker. PDPN is a transmembrane glycoprotein receptor that enables tumor cells to proliferate and migrate. This biomarker appears early in cancer transformation, persists through malignant progression, and causes poor clinical outcomes. An NIH funded human signal trial in oral cancer was recently completed and published supporting the continued development of our lead asset, MASL® (lenipagrusin alfa). Sentrimed is targeting Head and Neck Cancer (HNC) as the initial indication for this compound, and it has potential to treat other cancers.
Three tiers of evidence. One consistent signal.
In preclinical tumor models, MASL inhibited tumor growth not only at the local site but in distant tumors, supporting both local and systemic activity.
No adverse events.
NIH-funded first-in-human signal trial completed with no adverse events reported.
In surgically removed human Head and Neck Squamous Cell Carcinoma tumors, MASL appeared to stimulate immune response in vivo and inhibited cell migration and viability of cancer cells, including drug-resistant variants ex vivo.